MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis

Significance High-expression alleles of the cytokine macrophage migration inhibitory factor (MIF) are associated with severe joint destruction in autoimmune arthritis, but the mechanism for this effect is unknown. High-genotypic MIF-expressing joint fibroblasts produce high levels of MIF under inflammatory stimulation to up-regulate the surface expression of the MIF signaling coreceptor CD44 and promote its alternative splicing into invasive, tumor-associated isoforms, which contribute to the invasive and tissue-destructive character of the rheumatoid joint synovium. These findings support a precision medicine approach to the treatment of rheumatoid arthritis by pharmacologically targeting the MIF pathway in high-genotypic MIF-expressing patients. Fibroblast-like synoviocytes mediate joint destruction in rheumatoid arthritis and exhibit sustained proinflammatory and invasive properties. CD44 is a polymorphic transmembrane protein with defined roles in matrix interaction and tumor invasion that is also a signaling coreceptor for macrophage migration inhibitory factor (MIF), which engages cell surface CD74. High-expression MIF alleles (rs5844572) are associated with rheumatoid joint erosion, but whether MIF signaling through the CD74/CD44 receptor complex promotes upstream autoimmune responses or contributes directly to synovial joint destruction is unknown. We report here the functional regulation of CD44 by an autocrine pathway in synovial fibroblasts that is driven by high-expression MIF alleles to up-regulate an inflammatory and invasive phenotype. MIF increases CD44 expression, promotes its recruitment into a functional signal transduction complex, and stimulates alternative exon splicing, leading to expression of the CD44v3–v6 isoforms associated with oncogenic invasion. CD44 recruitment into the MIF receptor complex, downstream MAPK and RhoA signaling, and invasive phenotype require MIF and CD74 and are reduced by MIF pathway antagonists. These data support a functional role for high-MIF expression alleles and the two-component CD74/CD44 MIF receptor in rheumatoid arthritis and suggest that pharmacologic inhibition of this pathway may offer a specific means to interfere with progressive joint destruction.

[1]  Weiling Fu,et al.  Transcription factor ICBP90 regulates the MIF promoter and immune susceptibility locus. , 2016, The Journal of clinical investigation.

[2]  S. Gaffen IL-17 receptor composition , 2015, Nature Reviews Immunology.

[3]  W. L. Jorgensen,et al.  Macrophage Migration Inhibitory Factor Is Detrimental in Pneumococcal Pneumonia and a Target for Therapeutic Immunomodulation. , 2015, The Journal of infectious diseases.

[4]  G. Fingerle-Rowson,et al.  Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis. , 2015, Cytokine.

[5]  R. Bucala,et al.  The integral role of CD74 in antigen presentation, MIF signal transduction, and B cell survival and homeostasis. , 2014, Mini reviews in medicinal chemistry.

[6]  S. Kummerfeld,et al.  PILRα Negatively Regulates Mouse Inflammatory Arthritis , 2014, The Journal of Immunology.

[7]  K. Sheng,et al.  Macrophage migration inhibitory factor receptor CD74 mediates alphavirus-induced arthritis and myositis in murine models of alphavirus infection. , 2013, Arthritis and rheumatism.

[8]  W. L. Jorgensen,et al.  Limiting Cardiac Ischemic Injury by Pharmacological Augmentation of Macrophage Migration Inhibitory Factor–AMP-Activated Protein Kinase Signal Transduction , 2013, Circulation.

[9]  K. Sheng,et al.  MIF receptor CD74 mediates alphavirus-induced arthritis and myositis: Requirement for CD74 in Alphavirus Arthritis and Myositis , 2013 .

[10]  L. Leng,et al.  Macrophage-derived, macrophage migration inhibitory factor (MIF) is necessary to induce disease in the K/BxN serum-induced model of arthritis , 2013, Rheumatology International.

[11]  Chun-Yin Huang,et al.  Macrophage migration inhibitory factor increases cell motility and up‐regulates αvβ3 integrin in human chondrosarcoma cells , 2012, Journal of cellular biochemistry.

[12]  H. Ehrlich,et al.  Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the β-Sheet Structure of MIF* , 2012, The Journal of Biological Chemistry.

[13]  Ruth R. Montgomery,et al.  Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[14]  Julia L. Gregory,et al.  Macrophage Migration Inhibitory Factor and CD74 Regulate Macrophage Chemotactic Responses via MAPK and Rho GTPase , 2011, The Journal of Immunology.

[15]  Zhinan Yin,et al.  A Small-Molecule Macrophage Migration Inhibitory Factor Antagonist Protects against Glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr Mice , 2011, The Journal of Immunology.

[16]  W. L. Jorgensen,et al.  Receptor agonists of macrophage migration inhibitory factor. , 2010, Bioorganic & medicinal chemistry letters.

[17]  Zoe Cournia,et al.  Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). , 2010, Bioorganic & medicinal chemistry letters.

[18]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[19]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[20]  E. Karlson,et al.  Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. , 2010, Arthritis and rheumatism.

[21]  L. Leng,et al.  Autoimmune diseases: MIF as a therapeutic target , 2010, Expert opinion on therapeutic targets.

[22]  P. Robbins,et al.  Synovial fibroblasts spread rheumatoid arthritis to unaffected joints , 2009, Nature Medicine.

[23]  J. Bernhagen,et al.  A functional heteromeric MIF receptor formed by CD74 and CXCR4 , 2009, FEBS letters.

[24]  J. Bernhagen,et al.  The Golgi-Associated Protein p115 Mediates the Secretion of Macrophage Migration Inhibitory Factor1 , 2009, The Journal of Immunology.

[25]  T. Ludwig,et al.  CD44 Variant Isoforms Promote Metastasis Formation by a Tumor Cell-Matrix Cross-talk That Supports Adhesion and Apoptosis Resistance , 2009, Molecular Cancer Research.

[26]  J. Byrd,et al.  Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. , 2008, Blood.

[27]  J. Bernhagen,et al.  Interactions of T helper cells with fibroblast-like synoviocytes: up-regulation of matrix metalloproteinases by macrophage migration inhibitory factor from both Th1 and Th2 cells. , 2008, Arthritis and rheumatism.

[28]  R. Weinberg,et al.  Growth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 Expression , 2008, Cell.

[29]  C. Metz,et al.  Macrophage migration inhibitory factor up-regulates alpha(v)beta(3) integrin and vascular endothelial growth factor expression in endometrial adenocarcinoma cell line Ishikawa. , 2008, Journal of reproductive immunology.

[30]  L. Leng,et al.  Macrophage Migration Inhibitory Factor Induces B Cell Survival by Activation of a CD74-CD44 Receptor Complex* , 2008, Journal of Biological Chemistry.

[31]  D. Stepensky,et al.  FRETcalc plugin for calculation of FRET in non-continuous intracellular compartments. , 2007, Biochemical and biophysical research communications.

[32]  A. Koch The pathogenesis of rheumatoid arthritis. , 2007, American journal of orthopedics.

[33]  Georg Schett,et al.  Cytokines in the pathogenesis of rheumatoid arthritis , 2007, Nature Reviews Immunology.

[34]  L. Bourguignon,et al.  Association of CD44 V3‐containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer , 2007, Head & neck.

[35]  Wan-Uk Kim,et al.  Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis , 2007, Arthritis research & therapy.

[36]  K. Tung,et al.  Phosphorylated ERM Is Responsible for Increased T Cell Polarization, Adhesion, and Migration in Patients with Systemic Lupus Erythematosus12 , 2007, The Journal of Immunology.

[37]  L. Leng,et al.  CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. , 2006, Immunity.

[38]  S. Stamm,et al.  Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. , 2006, Cancer research.

[39]  J. Bernhagen,et al.  MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis , 2006, Nature Reviews Drug Discovery.

[40]  A. Maitra,et al.  Cutting Edge: Evidence for Ligand-Independent Multimerization of the IL-17 Receptor1 , 2006, The Journal of Immunology.

[41]  T. Calandra,et al.  Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  G. Prestwich,et al.  Regulation of lung injury and repair by Toll-like receptors and hyaluronan , 2005, Nature Medicine.

[43]  B. Franke,et al.  Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. , 2005, Arthritis and rheumatism.

[44]  M. Symons,et al.  Rho GTPase-dependent Signaling Is Required for Macrophage Migration Inhibitory Factor-mediated Expression of Cyclin D1* , 2005, Journal of Biological Chemistry.

[45]  E. Zeggini,et al.  A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. , 2004, Arthritis and rheumatism.

[46]  O. Petrenko,et al.  The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R. Bucala,et al.  Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. , 2003, Arthritis and rheumatism.

[48]  L. Leng,et al.  MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.

[49]  R. Bucala,et al.  Adhesion-dependent Signaling by Macrophage Migration Inhibitory Factor (MIF)* , 2003, The Journal of Biological Chemistry.

[50]  E. Génot,et al.  Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints. , 2002, Arthritis and rheumatism.

[51]  R. Bucala,et al.  Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. , 2002, Rheumatology.

[52]  P. Gregersen,et al.  A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis , 2002, Genes and Immunity.

[53]  Lilly Y. W. Bourguignon,et al.  Signaling Properties of Hyaluronan Receptors* , 2002, The Journal of Biological Chemistry.

[54]  E. Morand,et al.  Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. , 2001, Arthritis and rheumatism.

[55]  R. Gay,et al.  Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts. , 2000, Arthritis and rheumatism.

[56]  R. Bucala,et al.  Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. , 2000, Arthritis and rheumatism.

[57]  R. Bucala,et al.  Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. , 1999, Arthritis and rheumatism.

[58]  Tina Peng,et al.  Sustained Mitogen-activated Protein Kinase (MAPK) and Cytoplasmic Phospholipase A2 Activation by Macrophage Migration Inhibitory Factor (MIF) , 1999, The Journal of Biological Chemistry.

[59]  D. Green,et al.  Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[60]  L. Pirilä,et al.  H-ras oncogene point mutations in arthritic synovium. , 1997, Arthritis and rheumatism.

[61]  H. Diamond,et al.  Interleukin-1beta-stimulated invasion of articular cartilage by rheumatoid synovial fibroblasts is inhibited by antibodies to specific integrin receptors and by collagenase inhibitors. , 1997, Arthritis and rheumatism.

[62]  R. Holmdahl,et al.  Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. , 1997, Journal of immunology.

[63]  R. Bucala,et al.  Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome , 1997, Nature Medicine.

[64]  T. Glant,et al.  Anti-CD44 treatment abrogates tissue aedema and leukocyte infiltration in murine arthrtis , 1995, Nature Medicine.

[65]  J. Bernhagen,et al.  Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). , 1994, Biochemistry.

[66]  Mark S. Anderson,et al.  The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44 , 1993, Cell.

[67]  R. Bucala,et al.  Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts , 1991, The Journal of experimental medicine.

[68]  N. Bottini,et al.  Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors , 2013, Nature Reviews Rheumatology.

[69]  J. Smolen,et al.  Expression patterns of CD44 and CD44 splice variants in patients with rheumatoid arthritis. , 2012, Clinical and experimental rheumatology.

[70]  R. Bucala MIF, MIF Alleles, and Prospects for Therapeutic Intervention in Autoimmunity , 2012, Journal of Clinical Immunology.

[71]  Peter Zenz,et al.  The rationale of pharmacoeconomic analysis in rheumatologic indications. , 2012 .

[72]  P. Herrlich,et al.  CD44: From adhesion molecules to signalling regulators , 2003, Nature Reviews Molecular Cell Biology.

[73]  R. Bucala,et al.  Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. , 2003, Arthritis and rheumatism.

[74]  J. Sleeman,et al.  CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. , 1999, Cancer research.

[75]  G. Firestein Somatic mutation in the tumore suppressor gene in erosive rheumatoid arthritis synovium , 1997 .